Allergan and Editas Medicine Enter into Strategic R&D Alliance – The FINANCIAL
The FINANCIAL |
Allergan and Editas Medicine Enter into Strategic R&D Alliance
The FINANCIAL The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine's lead program is being … |
